Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

phase icon View trials
by phase
cancer type icon View trials by
cancer type
target icon View trials by
therapeutic target
NILEX=new indication line extension; NME=new molecular entity.

phase 2

CLL/SLL or NHL
BTK Inhibitor Enrolling
Pirtobrutinib, LOXO-305
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Prostate Cancer
Abemaciclib, LY2835219
Prostate Cancer
Abemaciclib, LY2835219
Pancreatic Cancer
Olaratumab, LY3012207, IMC‑3G3
NSCLC, Medullary Thyroid Cancer, Papillary Thyroid Carcinoma, or Other Advanced Solid Tumors
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723
Pediatric Cancer
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723
Pediatric Cancer
Ramucirumab, LY3009806, IMC‑1121B
Pediatric Cancer
Ramucirumab, LY3009806, IMC‑1121B